Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation

Authors

  • Gilad Yahalom MD,

    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
    • Both authors contributed equally to this manuscript

  • Yael Orlev BSc,

    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    2. Department of Epidemiology and Preventive Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
    • Both authors contributed equally to this manuscript

  • Oren S. Cohen MD,

    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Evgenia Kozlova MSc, RN,

    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Eitan Friedman MD, PhD,,

    1. The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Tel- Hashomer, Israel
    2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Rivka Inzelberg MD,

    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Sharon Hassin-Baer MD

    Corresponding author
    1. The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel
    2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Correspondence to: Dr. Sharon Hassin-Baer, The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel- Hashomer, Ramat Gan, 52621 Israel, E-mail: shassin@post.tau.ac.il

    Search for more papers by this author

  • Funding agencies: This study was supported by the Bharier Medical Fund, in memory of Nat and Sophie Bharier.

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Introduction

In this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.

Methods

Consecutive PD patients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3).

Results

Overall, 405 AJ PD patients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001).

Conclusion

The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PD patients. © 2014 International Parkinson and Movement Disorder Society

Ancillary